Back to today’s briefing

Story perspectives

Biotech Stocks Plummet After Controversial Health Secretary Appointment

4/2/2025

28 3

Summary

Story summary

The biotech sector is reeling from the appointment of Robert F. Kennedy Jr. as U.S. Health Secretary, coupled with the resignation of FDA official Peter Marks. Vaccine stocks, notably Moderna and Novavax, have taken a nosedive as analysts warn of looming regulatory chaos and heightened public health risks stemming from Kennedy's controversial anti-vaccine views.

1 of 1

Story summary

The biotech sector is reeling from the appointment of Robert F. Kennedy Jr. as U.S. Health Secretary, coupled with the resignation of FDA official Peter Marks. Vaccine stocks, notably Moderna and Novavax, have taken a nosedive as analysts warn of looming regulatory chaos and heightened public health risks stemming from Kennedy's controversial anti-vaccine views.